Granted Patent
B2
US 12,709,752 · App. 19/306,057 · Granted Aug 18, 2026
Compositions and methods for inhibiting XDH expression
Assignee:
NOVO NORDISK A/S
View Patent ↗
Loading inventors, assignments & file history…
Abstract
Oligonucleotides are provided herein that inhibit XDH expression. Also provided are compositions including the same and uses thereof, particularly uses relating to treating diseases, disorders and/or conditions associated with aberrant XDH expression.
Claims (5)
1 . An siRNA comprising a first RNA oligonucleotide and a second RNA oligonucleotide, wherein the first RNA oligonucleotide consists of the sequence set forth in SEQ ID: 23, and the second RNA oligonucleotide consists of the sequence set forth in SEQ ID: 24.
2 . A pharmaceutical composition comprising the siRNA according to claim 1 and a pharmaceutically acceptable carrier, delivery agent or excipient.
3 . A method of treating gout in a subject in need thereof, the method comprising administering to the subject the siRNA of claim 1 .
4 . A method for reducing xanthine dehydrogenase (XDH) expression in a subject in need thereof, the method comprising administering to the subject the siRNA of claim 1 .
5 . A method for reducing XDH expression in a cell, the method comprising contacting the cell with the siRNA of claim 1 .
Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded Jan 22, 2026
From: OSTRIKER, ALLISON CHERRY; KOSER, MARTIN LEE
To: DICERNA PHARMACEUTICALS, INC.
Reel/Frame 073551/0780 →
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded Jan 22, 2026
From: DICERNA PHARMACEUTICALS, INC.
To: NOVO NORDISK A/S
Reel/Frame 074477/0473 →
Continuity (2)
Provisional Application
63685395
· Aug 21, 2024
Related Publication
20260055414A1
· Feb 26, 2026
References Cited (183)
US 7491805B2
· Vargeese et al.
· 2009
[cited by applicant]
US 7645747B2
· Boojamra et al.
· 2010
[cited by applicant]
US 7696345B2
· Allerson et al.
· 2010
[cited by applicant]
US 7750144B2
· Zamore et al.
· 2010
[cited by applicant]
US 7786290B2
· Woppmann et al.
· 2010
[cited by applicant]
US 7923547B2
· McSwiggen et al.
· 2011
[cited by applicant]
US 8084598B1
· Bentwich
· 2011
[cited by applicant]
US 8084599B2
· Rossi et al.
· 2011
[cited by applicant]
US 8273866B2
· McSwiggen et al.
· 2012
[cited by applicant]
US 8334373B2
· Vornlocher et al.
· 2012
[cited by applicant]
US 8513207B2
· Brown
· 2013
[cited by applicant]
US 8779114B2
· Han et al.
· 2014
[cited by applicant]
US 8877917B2
· Forst et al.
· 2014
[cited by applicant]
US 8883996B2
· Rossi et al.
· 2014
[cited by applicant]
US 8927513B2
· Manoharan et al.
· 2015
[cited by applicant]
US 8927705B2
· Brown
· 2015
[cited by applicant]
US 8987435B2
· Swayze et al.
· 2015
[cited by applicant]
US 8993532B2
· Hannon et al.
· 2015
[cited by applicant]
US 9012138B2
· Tuschl et al.
· 2015
[cited by applicant]
US 9012621B2
· Tuschl et al.
· 2015
[cited by applicant]
US 9074213B2
· Kreutzer et al.
· 2015
[cited by applicant]
US 9193753B2
· Tuschl et al.
· 2015
[cited by applicant]
US 9222091B2
· Manoharan et al.
· 2015
[cited by applicant]
US 9260471B2
· Cancilla et al.
· 2016
[cited by applicant]
US 9320798B2
· Brown
· 2016
[cited by applicant]
US 9326941B2
· Chae et al.
· 2016
[cited by applicant]
US 9328345B2
· Li et al.
· 2016
[cited by applicant]
US 9549983B2
· Brown et al.
· 2017
[cited by applicant]
US 9771583B2
· Puri et al.
· 2017
[cited by applicant]
US 9790498B2
· Brown et al.
· 2017
[cited by applicant]
US 9943604B2
· Seth et al.
· 2018
[cited by applicant]
US 20090176725A1
· Morrissey et al.
· 2009
[cited by applicant]
US 20090220587A1
· Allon et al.
· 2009
[cited by applicant]
US 20090285881A1
· Dande et al.
· 2009
[cited by applicant]
US 20100055168A1
· Dande et al.
· 2010
[cited by applicant]
US 20100063135A1
· Dande et al.
· 2010
[cited by applicant]
US 20100173973A1
· Brown
· 2010
[cited by applicant]
US 20100197023A1
· Leake et al.
· 2010
[cited by applicant]
US 20100204305A1
· Young et al.
· 2010
[cited by applicant]
US 20110111056A1
· Basu et al.
· 2011
[cited by applicant]
US 20110118340A1
· Manoharan et al.
· 2011
[cited by applicant]
US 20110288147A1
· Brown
· 2011
[cited by applicant]
US 20120095200A1
· Brown
· 2012
[cited by applicant]
US 20120121515A1
· Dang et al.
· 2012
[cited by applicant]
US 20150203847A1
· Manoharan et al.
· 2015
[cited by applicant]
US 20190002880A1
· Woolf et al.
· 2019
[cited by applicant]
US 20200031862A1
· Brown et al.
· 2020
[cited by applicant]
US 20220135972A1
· Yokota et al.
· 2022
[cited by applicant]
US 20220170025A1
· Brown et al.
· 2022
[cited by applicant]
US 20220307024A1
· Nair et al.
· 2022
[cited by applicant]
US 20220389430A1
· Wang et al.
· 2022
[cited by applicant]
US 20220411801A1
· McIninch et al.
· 2022
[cited by applicant]
US 20230002773A1
· Nicholas et al.
· 2023
[cited by applicant]
US 20230069235A1
· Brown et al.
· 2023
[cited by applicant]
US 20230089478A1
· Cardia et al.
· 2023
[cited by applicant]
US 20230123981A1
· Wang et al.
· 2023
[cited by applicant]
US 20230277675A1
· Wang et al.
· 2023
[cited by applicant]
US 20230287424A1
· Brown et al.
· 2023
[cited by applicant]
US 20240287512A1
· Grim et al.
· 2024
[cited by applicant]
US 20240287513A1
· Rigo et al.
· 2024
[cited by applicant]
US 20240360455A1
· Nair et al.
· 2024
[cited by applicant]
US 20250163097A1
· Komisarski et al.
· 2025
[cited by applicant]
CA 2677068A1
· 2011
[cited by applicant]
CA 3209281A1
· 2022
[cited by examiner]
EP 2513334A1
· 2012
[cited by applicant]
EP 2774989A1
· 2014
[cited by applicant]
EP 2280070B1
· 2015
[cited by applicant]
EP 3503730A1
· 2019
[cited by applicant]
EP 4021915A1
· 2022
[cited by applicant]
EP 4225919A1
· 2023
[cited by applicant]
EP 4284933A1
· 2023
[cited by applicant]
EP 4392556A1
· 2024
[cited by applicant]
EP 4430190A2
· 2024
[cited by applicant]
EP 4426839A1
· 2024
[cited by applicant]
EP 4493568A1
· 2025
[cited by applicant]
WO WO2004045543A2
· 2004
[cited by applicant]
WO WO2009129385A1
· 2009
[cited by applicant]
WO WO2010030730A1
· 2010
[cited by applicant]
WO WO2010033225A2
· 2010
[cited by applicant]
WO WO2010054405A1
· 2010
[cited by applicant]
WO WO2010141726A2
· 2010
[cited by applicant]
WO WO2011005860A2
· 2011
[cited by applicant]
WO WO2011022460A1
· 2011
[cited by applicant]
WO WO2011072292A2
· 2011
[cited by applicant]
WO WO2011075188A1
· 2011
[cited by applicant]
WO WO2011075656A1
· 2011
[cited by applicant]
WO WO2011123621A2
· 2011
[cited by applicant]
WO WO2011133871A2
· 2011
[cited by applicant]
WO WO2012000104A1
· 2012
[cited by applicant]
WO WO2012030683A2
· 2012
[cited by applicant]
WO WO2013032643A2
· 2013
[cited by applicant]
WO WO2013033230A1
· 2013
[cited by applicant]
WO WO2013074974A2
· 2013
[cited by applicant]
WO WO2013165816A2
· 2013
[cited by applicant]
WO WO2015069932A1
· 2015
[cited by applicant]
WO WO2015085158A1
· 2015
[cited by applicant]
WO WO2015106128A2
· 2015
[cited by applicant]
WO WO2016028649A1
· 2016
[cited by applicant]
WO WO2016100401A1
· 2016
[cited by applicant]
WO WO2016149020A1
· 2016
[cited by applicant]
WO WO2016149313A1
· 2016
[cited by applicant]
WO WO2016168286A1
· 2016
[cited by applicant]
WO WO2018039364A1
· 2018
[cited by applicant]
WO WO2018045317A1
· 2018
[cited by applicant]
WO WO2018185241A1
· 2018
[cited by applicant]
WO WO2019200124A1
· 2019
[cited by applicant]
WO WO2019217459A1
· 2019
[cited by applicant]
WO WO2019232255A1
· 2019
[cited by applicant]
WO WO2020123083A1
· 2020
[cited by applicant]
WO WO2020132227A2
· 2020
[cited by applicant]
WO WO2020206350A1
· 2020
[cited by applicant]
WO WO2020226960A1
· 2020
[cited by applicant]
WO WO2020257194A1
· 2020
[cited by applicant]
WO WO2021067744A1
· 2021
[cited by applicant]
WO WO2021146488A1
· 2021
[cited by applicant]
WO WO2022187622A1
· 2022
[cited by applicant]
WO WO2022269346A2
· 2022
[cited by applicant]
WO WO2022271573A1
· 2022
[cited by applicant]
WO WO2023081822A1
· 2023
[cited by applicant]
WO WO2023245061A2
· 2023
[cited by applicant]
WO WO2024040041A1
· 2024
[cited by applicant]
WO WO2024073709A2
· 2024
[cited by applicant]
WO WO2024216155A1
· 2024
[cited by applicant]
WO WO2024233864A2
· 2024
[cited by applicant]
WO WO2024249680A2
· 2024
[cited by applicant]
WO WO2025054459A1
· 2025
[cited by applicant]
Elbashir et al. (The EMBO Journal, vol. 20, No. 23, pp. 6877-6888, 2001).
[cited by examiner]
Zhang et al. (Biologia Plantarum, 57(3), 547-554, 2013).
[cited by examiner]
Wang et al. (Hindawi Publishing Corporation, Mediators of Inflammation, vol. 2015, Article ID 680853, 1-6).
[cited by examiner]
Sliva et al. (e Virology Journal 2010, 7:248, 1-11).
[cited by examiner]
McIntyre et al. (BMC Molecular Biology 2011, 12:34, 1-12).
[cited by examiner]
Antao et al., “A thermodynamic study of unusually stable RNA and DNA hairpins”, Nucleic Acid Research, 1991, vol. 19, No. 21, pp. 5901-5905.
[cited by applicant]
Cheong et al., “Solution structure of an unusually stable RNA hairpin, 5GGAC(UUCG)GUCC”, Nature, Aug. 1990, vol. 346, pp. 680-682.
[cited by applicant]
Cornish-Bowden, “Nomenclature for incompletely specified bases in nucleic acid sequences: recommendations 1984”, Nucleic Acids Res., May 1985, vol. 13, No. 9, pp. 3021-3030.
[cited by applicant]
Heus et al., “Structural Features That Give Rise to the Unusual Stability if RNA Hairpins Containing GNRA Loops”, Science, 1991, vol. 253, pp. 191-194.
[cited by applicant]
Huch et al., “In vitro expansion of single Lgr5+ liver stem cells induced by Wnt-driven regeneration”, Nature, Feb. 2013, vol. 494, pp. 247-250.
[cited by applicant]
Imanishi et al., “BNAs: novel nucleic acid analogs with a bridged sugar moiety”, Chem Commun. (Camb), Aug. 2002, vol. 21, pp. 1653-1659.
[cited by applicant]
Koshkin et al., “LNA (Locked Nucleic Acids): Synthesis of the adenine, cytosine, guanine, 5-methylcytosine, thymine and uracil bicyclonucleoside monomers, oligomerisation, and unprecedented nucleic acid recognition”, Te…
[cited by applicant]
Nakano et al., “Selection for thermodynamically stable DNA tetraloops using temperature gradient gel electrophoresis reveals four motifs: d(cGNNAg), d(cGNABg), d(cCNNGg), and d(gCNNGc)”, Biochemistry, Dec. 2002, vol. 41…
[cited by applicant]
Prakash et al., “Identification of metabolically stable 5′-phosphate analogs that support single- stranded siRNA activity”, Nucleic Acids Res., Mar. 2015, vol. 43, pp. 2993-3011.
[cited by applicant]
Shinji et al., Nippon Kagakkai Koen Yokoshu, 2000, vol. 78, p. 731.
[cited by applicant]
Snead et al., “5′ Unlocked Nucleic Acid Modification Improves siRNA Targeting”, Mol. Ther-Nucl. Acids, Jul. 2013, vol. 2, No. 7, e103, pp. 1-7.
[cited by applicant]
Woese et al., “Architecture of ribosomal RNA: constraints on the sequence of “tetra-loops””, PNAS, Nov. 1990, vol. 87, pp. 8467-8471.
[cited by applicant]
Allerson et al., “Fully 2′-Modified Oligonucleotide Duplexes with Improved in Vitro Potency and Stability Compared to Unmodified Small Interfering RNA”, Journal of Medicinal Chemistry, vol. 48, No. 4, Jan. 20, 2005, pp.…
[cited by applicant]
Biscans et al., “The valency of fatty acid conjugates impacts siRNA pharmacokinetics, distribution, and efficacy in vivo”. Journal of controlled release. May 28, 2019; 302: 116-25. Epub Mar. 30, 2019.
[cited by applicant]
Bottaro et al., “Mapping the Universe of RNA Tetraloop Folds”, Biophysical Journal, 2017, vol. 113, pp. 257-267.
[cited by applicant]
Chang et al., “Asymmetric shorter-duplex siRNA structures trigger efficient gene silencing with reduced nonspecific effects”, Mol Ther. Apr. 2009;17(4):725-32.
[cited by applicant]
Chernikov et al., “Current Development of siRNA Bioconjugates: From Research to the Clinic,” Front Pharmacol. 2019;10:444.
[cited by applicant]
Dicerna Pharmaceuticals, Inc., “Taking RNAi under the skin,” Nature.com. 2016:B12; Retrieved from the Internet: https://media.nature.com/original/magazine-assets/d43747-020-00189-y/d43747-020-00189-y.pdf.
[cited by applicant]
Foster, et al., “Advanced siRNA Designs Further Improve In Vivo Performance of GalNAc-siRNA Conjugates”, Molecular Therapy, vol. 26, No. 3, Mar. 2018, pp. 708-717.
[cited by applicant]
Hall, “Mighty tiny”, RNA, Apr. 1, 2015, vol. 21, pp. 630-631.
[cited by applicant]
Kenski, et al., “siRNA-optimized Modifications for Enhanced In Vivo Activity”, Molecular Therapy-Nucleic Acids, vol. 1, e5, Jan. 24, 2012, pp. 1-8.
[cited by applicant]
Koizumi, M., “Nucleic acids therapeutics using chemical modified oligonucleotides,”. Medchem News, vol. 25, No. 2, May 1, 2015, pp. 103-108.
[cited by applicant]
Kubo et al., “Lipid-Conjugated 27-Nucleotide Double-Stranded RNAs with Dicer-Substrate Potency Enhance RNAi-Mediated Gene Silencing”, Molecular Pharmaceuticals, May 7, 2012, vol. 9, No. 5, pp. 1374-1382.
[cited by applicant]
Leonard et al., “Effects of osmolytes and macromolecular crowders on stable GAAA tetraloops and their preference for a CG closing base pair”, PeerJ, 2018, 6:e4236; DOI 10.7717/peerj.4236, 16 pages.
[cited by applicant]
Mikula, H.; Svatunek, D.; Lumpi, D.; Glocklhofer, F.; Hametner, Frolich, DMDO preparation and glycal epoxidation, J. Org, Process Res. Dev. 2013, 17, 313-316.
[cited by applicant]
Minikel, “Antisense part III: chemistries,” CureFFI.org, Comparison of Chemical Modifications, Aug. 28, 2018, 16 Pages.
[cited by applicant]
Nair, et al., “Impact of Enhanced Metabolic Stability on Pharmacokinetics and Pharmacodynamics of GalNAc—siRNA Conjugates”, Nucleic Acids Research, vol. 45, No. 19, Published online Sep. 15, 2017, pp. 10969-10977, pp. 1…
[cited by applicant]
Podbevsek et al., “Solution-state structure of a fully alternately 2′-F/2′-OMe modified 42-nt dimeric siRNA construct,” Nucleic Acids Res. Nov. 2010;38(20):7298-307.
[cited by applicant]
Zhou et al., “Current RNA-based Therapeutics in Clinical Trials,” Curr Gene Ther. 2019;19(3):172-196.
[cited by applicant]
International Search Report and Written Opinion for International Application No. PCT/IB25/00418 dated Feb. 20, 2026.
[cited by applicant]